Benzodiazepines and Heightened Aggressive Behavior in Rats: Reduction by GABA(A)/alpha(1) Receptor Antagonists
Overview
Affiliations
Rationale: Positive modulators of the benzodiazepine/GABA(A) receptor complex can heighten aggressive behavior; the GABA(A)/alpha(1) subunit may play a critical role in benzodiazepine-modulated aggressive behavior.
Objective: The carboline derivatives, beta-CCt and 3-PBC, antagonists with preferential action at the GABA(A) receptors with alpha(1) subunits, may antagonize benzodiazepine-heightened aggression, thus implicating the alpha(1) subunit in heightened aggression.
Methods: The GABA(A) receptor agonist 4,5,6,7-tetrahydroisoxazolo[5,4c]-pyridin-3-ol (THIP) (0.01-3.0 mg/kg), and the benzodiazepine receptor agonists midazolam (0.3-3.0 mg/kg) and triazolam (0.003-3.0 mg/kg) were administered to adult male resident rats to assess the drugs' effects on their aggressive behavior toward an intruder. Then beta-CCt (0.3-10.0 mg/kg) and 3-PBC (0.3-17.0 mg/kg) were each administered in conjunction with midazolam. The salient elements of aggressive and non-aggressive behavior were measured by analyzing video recordings and encoding each behavioral act and posture in terms of its frequency and duration of occurrence.
Results: Midazolam significantly increased the duration of aggressive behaviors at 1.0 and 1.7 mg/kg, and triazolam increased attack bite frequency at 0.03 mg/kg, both implicating GABA(A) receptors with benzodiazepine binding sites in aggressive behavior. In the present dose range, THIP did not affect any behaviors. The broad-spectrum benzodiazepine antagonist, flumazenil (1.0 mg/kg), antagonized the aggression-heightening effects of midazolam. beta-CCt (0.3-10.0 mg/kg) and 3-PBC (0.3-17.0 mg/kg) also antagonized the aggression-heightening effects of midazolam (1.0 mg/kg).
Conclusions: These results implicate both the GABA(A) gamma and alpha(1) subunits in benzodiazepine-heightened aggression.
Myers A, Baker K, Kubisch M, Russell-Lodrigue K, Bohm R J Am Assoc Lab Anim Sci. 2025; 64(1):146-154.
PMID: 40035278 PMC: 11808378. DOI: 10.30802/AALAS-JAALAS-24-088.
Premenstrual syndrome: new insights into etiology and review of treatment methods.
Modzelewski S, Oracz A, Zukow X, Ilendo K, Sledzikowka Z, Waszkiewicz N Front Psychiatry. 2024; 15:1363875.
PMID: 38716118 PMC: 11075635. DOI: 10.3389/fpsyt.2024.1363875.
Martinez R, Chou S, Fan Y, Chen Y, Goh K, Chen C Sci Rep. 2024; 14(1):1200.
PMID: 38216629 PMC: 10786834. DOI: 10.1038/s41598-024-51345-8.
Gatta E, Camussi D, Auta J, Guidotti A, Pandey S Pharmacol Ther. 2022; 240:108299.
PMID: 36323379 PMC: 9810076. DOI: 10.1016/j.pharmthera.2022.108299.
Kezar S, Baker K, Russell-Lodrigue K, Bohm R J Am Assoc Lab Anim Sci. 2022; 61(2):173-180.
PMID: 35148813 PMC: 8956219. DOI: 10.30802/AALAS-JAALAS-21-000059.